Halozyme Therapeutics | HALO - 贸易债权人



金融业
股票价格
USD
资产
USD 2.53B
现金及等价物
USD 133.82M
销售成本
USD 102.15M
流动资产
USD 825.21M
流动负债
USD 177.09M
债务
USD 1.51B
EBIT
USD -88.41M
EBITDA
USD 21.9M
员工
350
EPS每股收益
USD -0.24
股本和储备
USD 48.81M
销售毛利
USD 281.77M
债务利息支出
USD 4.91M
贷款资金
USD 2.14B
市值
USD 8.32B
净收入
USD -141.59M
营业费用
USD 211.07M
营业利润
USD -88.41M
普通股股本
USD 117.78M
PE价格收益
23.16
税前利润
USD 218.96M
销售收入
USD 451.76M
销售和管理费用
USD 64.64M
股票
USD 176.48M
贸易债权人
USD 20.9M
应收帐款人
USD 441.27M


贸易债权人 更改 日
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amarin USD 45.36M 8.64M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Baxter International USD 999M 46M 2025-12
Cara Therapeutics USD 4.08M 1.65M 2025-09
Cytokinetics USD 105.62M 83.53M 2025-12
DBV Technologies USD 39.82M 972K 2025-09
Eli Lilly USD 5.38B 1.12B 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Intrexon USD 4.85M 3.12M 2024-06
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
MannKind USD 9.03M 1.76M 2025-12
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Pfizer USD 5.02B 142M 2025-09
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12